dizocilpine-maleate and phenylalanyl-leucyl-phenylalanyl-glutaminyl-prolyl-glutaminyl-arginyl-phenylalaninamide

Neuropeptide FF (NPFF) belongs to a neuropeptide family including two receptors (NPFF(1) and NPFF(2)). NPFF system has been reported to play important roles in pain transmission. The aim of the present study was to investigate the roles of NPFF related peptides and their receptors in swim stress-induced analgesia (SIA). Nociceptive test was performed in mice stressed by forced swimming in water at 15 °C (cold water swimming) or 32 °C (warm water swimming). Warm water swimming produced a naloxone-mediated antinociceptive effect. This warm water swim SIA was dose-dependently antagonized by i.c.v. injection of NPFF and two related peptides (3-30 nmol), NPVF and dNPA, which exhibited the highest selectivities for NPFF(1) and NPFF(2) receptors, respectively. Moreover, the selective NPFF receptor antagonist RF9 (30 nmol) was inactive by itself, but prevented the effects of NPFF and related peptides. Cold-water swimming produced a wilder analgesic effect that was blocked by MK-801, but not naloxone. However, NPFF system failed to modify the cold water swim stress-induced analgesia. These findings demonstrated that NPFF and related peptides attenuated opioid-mediated form of SIA via NPFF receptors in the brain, but not non-opioid swim stress-induced analgesia. These data further support an anti-opioid character of NPFF system.

Topics: Adamantane; Analgesia; Analysis of Variance; Animals; Cold Temperature; Dipeptides; Dizocilpine Maleate; Dose-Response Relationship, Drug; Hot Temperature; Injections, Intra-Articular; Injections, Intraventricular; Male; Mice; Mice, Inbred Strains; Naloxone; Narcotic Antagonists; Neuropeptides; Neuroprotective Agents; Oligopeptides; Stress, Psychological; Swimming

This study examined the effects of glutamate receptor agonists on the release of neuropeptide FF-like immunoreactivity from rat spinal dorsal half slices. Glutamate (10 microM) only induced release in Mg(2+)-free medium enriched with glycine (1 microM) and with slight depolarization (15 mM K+). This effect was abolished by the NMDA receptor antagonist, 2-amino-5-phosphonovalerate (100 microM), suggesting major participation of NMDA receptors. The quisqualate and metabotropic receptor agonists, alpha-amino-3-hydroxy-5-methylisoxazole-4-propionate (AMPA) and trans-1-hydroxy-5-methylisoxazole-4-propionate (t-ACPD) respectively, had no effect at 10 microM. In contrast, NMDA dose dependently stimulated neuropeptide FF release, even in the presence of the Na+ channel blocker, tetrodotoxin (1 microM), suggesting that NMDA receptors involved in the release of neuropeptide FF are mainly located on nerve terminals. The NMDA receptor antagonists, 2-amino-5-phosphonovalerate or (+)-5-methyl-10-11-dihydro-5H-dibenzo [a,d]cyclohepten-5,10-imine (MK-801) (100 microM), blocked the 10 microM NMDA effect. Furthermore, neuropeptide FF-like material inhibited binding of [125I]Y8Fa, a radioiodinated analog of neuropeptide FF, to spinal membranes, suggesting physiological relevance of NMDA-induced release. Taken together, these results suggest a relationship between neuropeptide FF and NMDA receptors in the spinal cord.

Topics: 2-Amino-5-phosphonovalerate; alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid; Animals; Cycloleucine; Dizocilpine Maleate; Glutamic Acid; In Vitro Techniques; Iodine Radioisotopes; Male; Membranes; N-Methylaspartate; Neuropeptides; Neurotoxins; Oligopeptides; Radioimmunoassay; Radioligand Assay; Rats; Rats, Wistar; Receptors, N-Methyl-D-Aspartate; Spinal Cord